CD274 and non-small cell lung carcinoma: Comparing our data with those from the Checkmate 057 clinical trial in patients with advanced non-squamous NSCLC that had progressed to platinum-based therapy, a good response to immunotherapy was expected, considering that in those with PD-L1 expression ≥50%, the objective response rate exceeded 40% and the hazard ratio (HR) for overall survival was 0.32 [12].